173 related articles for article (PubMed ID: 36867773)
1. Prediction of pathological response after neoadjuvant chemotherapy using baseline FDG PET heterogeneity features in breast cancer.
Oliveira C; Oliveira F; Vaz SC; Marques HP; Cardoso F
Br J Radiol; 2023 Jun; 96(1146):20220655. PubMed ID: 36867773
[TBL] [Abstract][Full Text] [Related]
2. Baseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2- Breast Cancer.
Groheux D; Sanna A; Majdoub M; de Cremoux P; Giacchetti S; Teixeira L; Espié M; Merlet P; de Roquancourt A; Visvikis D; Hatt M; Resche-Rigon M; Hindié E
J Nucl Med; 2015 Jun; 56(6):824-31. PubMed ID: 25883123
[TBL] [Abstract][Full Text] [Related]
3. 18F-FDG PET/CT and PET for evaluation of pathological response to neoadjuvant chemotherapy in breast cancer: a meta-analysis.
Cheng X; Li Y; Liu B; Xu Z; Bao L; Wang J
Acta Radiol; 2012 Jul; 53(6):615-27. PubMed ID: 22734080
[TBL] [Abstract][Full Text] [Related]
4. The role of interim 18F-FDG PET/CT in predicting early response to neoadjuvant chemotherapy in breast cancer.
Pahk K; Rhee S; Cho J; Seo M; Lee S; Park T; Park S; Lee E; Park KH; Kim C; Eo JS; Kim S; Choe JG
Anticancer Res; 2014 Aug; 34(8):4447-55. PubMed ID: 25075084
[TBL] [Abstract][Full Text] [Related]
5. [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy.
Berriolo-Riedinger A; Touzery C; Riedinger JM; Toubeau M; Coudert B; Arnould L; Boichot C; Cochet A; Fumoleau P; Brunotte F
Eur J Nucl Med Mol Imaging; 2007 Dec; 34(12):1915-24. PubMed ID: 17579854
[TBL] [Abstract][Full Text] [Related]
6. The accuracy of
Tian F; Shen G; Deng Y; Diao W; Jia Z
Eur Radiol; 2017 Nov; 27(11):4786-4796. PubMed ID: 28477166
[TBL] [Abstract][Full Text] [Related]
7. Predicting Response to Neoadjuvant Chemotherapy Using 18F FDG PET-CT in Patients with Locally Advanced Breast Cancer.
Hulikal N; Gajjala SR; Kalawat T; Kadiyala S; Kottu R
Asian Pac J Cancer Prev; 2020 Jan; 21(1):93-98. PubMed ID: 31983170
[TBL] [Abstract][Full Text] [Related]
8. ¹⁸F-FDG PET/CT in the early prediction of pathological response in aggressive subtypes of breast cancer: review of the literature and recommendations for use in clinical trials.
Groheux D; Mankoff D; Espié M; Hindié E
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):983-993. PubMed ID: 26758726
[TBL] [Abstract][Full Text] [Related]
9. Early prediction of response to neoadjuvant chemotherapy in breast cancer patients: comparison of single-voxel (1)H-magnetic resonance spectroscopy and (18)F-fluorodeoxyglucose positron emission tomography.
Cho N; Im SA; Kang KW; Park IA; Song IC; Lee KH; Kim TY; Lee H; Chun IK; Yoon HJ; Moon WK
Eur Radiol; 2016 Jul; 26(7):2279-90. PubMed ID: 26376886
[TBL] [Abstract][Full Text] [Related]
10. [Value of fused 18F-FDG PET/CT images in predicting efficacy of neoadjuvant chemotherapy on breast cancer].
Li D; Chen JH; Wang J; Ling R; Yao Q; Wang L
Ai Zheng; 2007 Aug; 26(8):900-4. PubMed ID: 17697556
[TBL] [Abstract][Full Text] [Related]
11. The assessment of breast cancer response to neoadjuvant chemotherapy: comparison of magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography.
Park JS; Moon WK; Lyou CY; Cho N; Kang KW; Chung JK
Acta Radiol; 2011 Feb; 52(1):21-8. PubMed ID: 21498321
[TBL] [Abstract][Full Text] [Related]
12. 18F-FDG PET-Derived Tumor Blood Flow Changes After 1 Cycle of Neoadjuvant Chemotherapy Predicts Outcome in Triple-Negative Breast Cancer.
Humbert O; Riedinger JM; Vrigneaud JM; Kanoun S; Dygai-Cochet I; Berriolo-Riedinger A; Toubeau M; Depardon E; Lassere M; Tisserand S; Fumoleau P; Brunotte F; Cochet A
J Nucl Med; 2016 Nov; 57(11):1707-1712. PubMed ID: 27103025
[TBL] [Abstract][Full Text] [Related]
13. 18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.
Cheng J; Wang Y; Mo M; Bao X; Zhang Y; Liu G; Zhang J; Geng D
Oncotarget; 2015 Oct; 6(30):29388-95. PubMed ID: 26336821
[TBL] [Abstract][Full Text] [Related]
14. Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.
Coudert B; Pierga JY; Mouret-Reynier MA; Kerrou K; Ferrero JM; Petit T; Kerbrat P; Dupré PF; Bachelot T; Gabelle P; Giard S; Coeffic D; Bougnoux P; Prevost JB; Paintaud G; Thibault G; Hernandez J; Coudert M; Arnould L; Berriolo-Riedinger A
Lancet Oncol; 2014 Dec; 15(13):1493-1502. PubMed ID: 25456368
[TBL] [Abstract][Full Text] [Related]
15. FDG-PET/CT and MRI for Evaluation of Pathologic Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer: A Meta-Analysis of Diagnostic Accuracy Studies.
Sheikhbahaei S; Trahan TJ; Xiao J; Taghipour M; Mena E; Connolly RM; Subramaniam RM
Oncologist; 2016 Aug; 21(8):931-9. PubMed ID: 27401897
[TBL] [Abstract][Full Text] [Related]
16. Comparison between 18F-FDG PET image-derived indices for early prediction of response to neoadjuvant chemotherapy in breast cancer.
Hatt M; Groheux D; Martineau A; Espié M; Hindié E; Giacchetti S; de Roquancourt A; Visvikis D; Cheze-Le Rest C
J Nucl Med; 2013 Mar; 54(3):341-9. PubMed ID: 23327900
[TBL] [Abstract][Full Text] [Related]
17. Subtype-Guided
Wu S; Wang Y; Li J; Zhang N; Mo M; Klimberg S; Kaklamani V; Cochet A; Shao Z; Cheng J; Liu G
Oncologist; 2020 Apr; 25(4):e626-e633. PubMed ID: 32297448
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of [18F]FDG PET for pathological response of breast cancer to neo-adjuvant chemotherapy.
Kim SJ; Kim SK; Lee ES; Ro J; Kang Sh
Ann Oncol; 2004 Sep; 15(9):1352-7. PubMed ID: 15319241
[TBL] [Abstract][Full Text] [Related]
19. HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment.
Groheux D; Giacchetti S; Hatt M; Marty M; Vercellino L; de Roquancourt A; Cuvier C; Coussy F; Espié M; Hindié E
Br J Cancer; 2013 Sep; 109(5):1157-64. PubMed ID: 23942075
[TBL] [Abstract][Full Text] [Related]
20. Staging of locally advanced breast cancer and the prediction of response to neoadjuvant chemotherapy: complementary role of scintimammography and 18F-FDG PET/CT.
Evangelista L; Cervino AR; Michieletto S; Saibene T; Orvieto E; Bozza F; Ghiotto C
Q J Nucl Med Mol Imaging; 2017 Jun; 61(2):205-215. PubMed ID: 25501326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
